DPH2

Across TCGA pan-cancer cohorts, DPH2 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated DPH2 data layer compared with 26 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in cholangiocarcinoma (CHOL), where higher DPH2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated DPH2 expression acts as an unfavorable survival marker.

CHOL, UCEC, and LUAD are the cancer types where DPH2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CHOL	DFS	Median	All	0.045	0.486	.009	15	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LUAD	DFS	Median	All	0.049	0.814	<.001	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

DPH2–CHOL (DFS)

Open the CHOL breakdown →